{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:55:28Z","timestamp":1781916928250,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T00:00:00Z","timestamp":1457395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T00:00:00Z","timestamp":1457395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/leu.2016.59","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T04:41:21Z","timestamp":1460695281000},"page":"1562-1567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia"],"prefix":"10.1038","volume":"30","author":[{"given":"N","family":"Gunnarsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Stenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"W\u00e5llberg-Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Sandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bj\u00f6rkholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Dreimane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Markev\u00e4rn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Wadenvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sj\u00e4lander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,8]]},"reference":[{"key":"BFleu201659_CR1","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sj\u00f6berg J et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29: 2514\u20132520.","journal-title":"J Clin Oncol"},{"key":"BFleu201659_CR2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M H\u00f6glund","year":"2013","unstructured":"H\u00f6glund M, Sandin F, Hellstr\u00f6m K, Bj\u00f6reman M, Bj\u00f6rkholm M, Brune M et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 2013; 122: 1284\u20131292.","journal-title":"Blood"},{"key":"BFleu201659_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1667\/RR2892.1","volume":"179","author":"WL Hsu","year":"2013","unstructured":"Hsu WL, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res 2013; 179: 361\u2013382.","journal-title":"Radiat Res"},{"key":"BFleu201659_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bjh.13346","volume":"169","author":"N Gunnarsson","year":"2015","unstructured":"Gunnarsson N, Stenke L, Hoglund M, Sandin F, Bjorkholm M, Dreimane A et al. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol 2015; 169: 683\u2013688.","journal-title":"Br J Haematol"},{"key":"BFleu201659_CR5","first-page":"1083","volume":"23","author":"KJ Johnson","year":"2012","unstructured":"Johnson KJ, Blair CM, Fink JM, Cerhan JR, Roesler MA, Hirsch BA et al. Medical conditions and risk of adult myeloid leukemia. Cancer Causes Control 2012; 23: 1083\u20131089.","journal-title":"Cancer Causes Control"},{"key":"BFleu201659_CR6","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","volume":"29","author":"SY Kristinsson","year":"2011","unstructured":"Kristinsson SY, Bj\u00f6rkholm M, Hultcrantz M, Derolf \u00c5, Landgren O, Goldin LR . Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011; 29: 2897\u20132903.","journal-title":"J Clin Oncol"},{"key":"BFleu201659_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/jnci\/djq043","volume":"102","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson SY, Koshiol J, Bj\u00f6rkholm M, Goldin LR, McMaster ML, Turesson I et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst 2010; 102: 557\u2013567.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201659_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/jnci\/djj361","volume":"98","author":"O Landgren","year":"2006","unstructured":"Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006; 98: 1321\u20131330.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201659_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/bjh.12330","volume":"161","author":"K Hemminki","year":"2013","unstructured":"Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K . Subsequent leukaemia in autoimmune disease patients. Br J Haematol 2013; 161: 677\u2013687.","journal-title":"Br J Haematol"},{"key":"BFleu201659_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","volume":"48","author":"L Barlow","year":"2009","unstructured":"Barlow L, Westergren K, Holmberg L, Talb\u00e4ck M . The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009; 48: 27\u201333.","journal-title":"Acta Oncol"},{"key":"BFleu201659_CR11","first-page":"289","volume":"3","author":"DR Boggs","year":"1976","unstructured":"Boggs DR . The pathogenesis and clinical patterns of blastic crisis of chronic myeloid leukemia. Semin Oncol 1976; 3: 289\u2013296.","journal-title":"Semin Oncol"},{"key":"BFleu201659_CR12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1542\/peds.61.4.560","volume":"61","author":"WM Crist","year":"1978","unstructured":"Crist WM, Ragab AH, Ducos R . Lymphoblastic conversion in chronic myelogenous leukemia. Pediatrics 1978; 61: 560\u2013563.","journal-title":"Pediatrics"},{"key":"BFleu201659_CR13","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1080\/10428190410001723278","volume":"45","author":"M Loriaux","year":"2004","unstructured":"Loriaux M, Deininger M . Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 2004; 45: 2197\u20132203.","journal-title":"Leuk Lymphoma"},{"key":"BFleu201659_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450.","journal-title":"BMC Public Health"},{"key":"BFleu201659_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3324\/haematol.2011.056283","volume":"97","author":"SM Ramadan","year":"2012","unstructured":"Ramadan SM, Fouad TM, Summa V, Hasan S, Lo-Coco F . Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica 2012; 97: 805\u2013817.","journal-title":"Haematologica"},{"key":"BFleu201659_CR16","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","volume":"118","author":"H Frederiksen","year":"2011","unstructured":"Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, S\u00f8rensen HT . Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011; 118: 6515\u20136520.","journal-title":"Blood"},{"key":"BFleu201659_CR17","doi-asserted-by":"crossref","unstructured":"Miranda MB, Lauseker M, Proetel U, Schreiber A, Hanfstein B, Baerlocher GM et al. Secondary malignancies in CML patients \u2013 data from the German CML Study IV. ASH Annual Meeting Abstracts 2012; Abstract 3746.","DOI":"10.1182\/blood.V120.21.3746.3746"},{"key":"BFleu201659_CR18","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/aje\/kwq262","volume":"172","author":"P Rebora","year":"2010","unstructured":"Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M, Valsecchi MG . Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol 2010; 172: 1028\u20131033.","journal-title":"Am J Epidemiol"},{"key":"BFleu201659_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1200\/JCO.2008.17.5398","volume":"27","author":"AM Tsimberidou","year":"2009","unstructured":"Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S et al. Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma. J Clin Oncol 2009; 27: 904\u2013910.","journal-title":"J Clin Oncol"},{"key":"BFleu201659_CR20","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","volume":"100","author":"LA Anderson","year":"2009","unstructured":"Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA . Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009; 100: 822\u2013828.","journal-title":"Br J Cancer"},{"key":"BFleu201659_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","volume":"24","author":"E Baecklund","year":"2014","unstructured":"Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R . Lymphoma development in patients with autoimmune and inflammatory disorders\u2014what are the driving forces? Semin Cancer Biol 2014; 24: 61\u201370.","journal-title":"Semin Cancer Biol"},{"key":"BFleu201659_CR22","first-page":"33","volume":"44","author":"Z Krosi","year":"1988","unstructured":"Krosi Z, Casassus P, Valeyre D, Paolaggi JA, Amouroux J, Battesti JP . [Chronic myeloid leukemia during the development of sarcoidosis]. Rev Pneumol Clin 1988; 44: 33\u201335.","journal-title":"Rev Pneumol Clin"},{"key":"BFleu201659_CR23","first-page":"84","volume":"34","author":"S Banno","year":"1993","unstructured":"Banno S, Nitta M, Takada K, Wakita A, Iwaki O, Mitomo Y et al. [Chronic myelogenous leukemia complicated with sarcoidosis]. Rinsho Ketsueki 1993; 34: 84\u201386.","journal-title":"Rinsho Ketsueki"},{"key":"BFleu201659_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1365-2141.1992.tb02984.x","volume":"81","author":"UB Wandl","year":"1992","unstructured":"Wandl UB, Kloke O, Nagel-Hiemke M, Moritz T, Becher R, Opalka B et al. Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia. Br J Haematol 1992; 81: 516\u2013519.","journal-title":"Br J Haematol"},{"key":"BFleu201659_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/00007611-197906000-00004","volume":"72","author":"DS Cheng","year":"1979","unstructured":"Cheng DS, Kitahara M, Logan KH . Chronic granulocytic leukemia: long-term remission in a patient with familial sarcoidosis. South Med J 1979; 72: 645\u2013647.","journal-title":"South Med J"},{"issue":"5 Pt 1","key":"BFleu201659_CR26","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1164\/ajrccm.160.5.9904045","volume":"160","author":"J Askling","year":"1999","unstructured":"Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A . Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 1999; 160 (5 Pt 1): 1668\u20131672.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFleu201659_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/bjc.1974.64","volume":"29","author":"H Brincker","year":"1974","unstructured":"Brincker H, Wilbek E . The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer 1974; 29: 247\u2013251.","journal-title":"Br J Cancer"},{"key":"BFleu201659_CR28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1182\/blood-2013-05-501312","volume":"vol. 122","author":"M Bjorkholm","year":"2013","unstructured":"Bjorkholm M, Kristinsson SY, Landgren O, Goldin LR . No familial aggregation in chronic myeloid leukemia. Blood 2013; vol. 122: 460\u2013461.","journal-title":"Blood"},{"key":"BFleu201659_CR29","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.leukres.2014.08.002","volume":"38","author":"RP Gale","year":"2014","unstructured":"Gale RP, Hlatky L, Sachs RK, Radivoyevitch T . Why is there so much therapy-related AML and MDS and so little therapy-related CML? Leuk Res 2014; 38: 1162\u20131164.","journal-title":"Leuk Res"},{"key":"BFleu201659_CR30","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","volume":"121","author":"LM Morton","year":"2013","unstructured":"Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 2013; 121: 2996\u20133004.","journal-title":"Blood"},{"key":"BFleu201659_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.clml.2014.03.001","volume":"14","author":"A Quintas-Cardama","year":"2014","unstructured":"Quintas-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2014; 14: 401\u2013410.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFleu201659_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/10428199809058378","volume":"29","author":"RC Aguiar","year":"1998","unstructured":"Aguiar RC . Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma 1998; 29: 17\u201326.","journal-title":"Leuk Lymphoma"},{"key":"BFleu201659_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1200\/JCO.2010.31.3080","volume":"29","author":"M Iwanaga","year":"2011","unstructured":"Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol 2011; 29: 428\u2013434.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201659.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201659","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201659.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:42:28Z","timestamp":1781916148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,8]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFleu201659"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.59","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,8]]},"assertion":[{"value":"22 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AS had a consulting role for ARIAD. JR has received honoraria from ARIAD, Bristol-Myers Squibb and Novartis. MB have a consulting role for Roche, Tolero Pharmaceuticals and Nordic Nanovector, and received honoraria from Roche, Tolero Pharmaceuticals and Nordic Nanovector. ML have stock ownership in AstraZeneca and Pfizer. SW-J received honoraria from MDS. MH has a consulting role for Akinion Pharmaceuticals and has received honoraria from Janssen-Cilag. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}